NCT01648517View on ClinicalTrials.gov

Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 27, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Non-small Cell Lung Carcinoma
Interventions
DRUG

chemotherapy

A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)

DRUG

chemotherapy

Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1

Trial Locations (1)

120-752

Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT01648517 - Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy | Biotech Hunter | Biotech Hunter